Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Convertible Debt (2024)

NRX Pharmaceuticals (NRXP) has disclosed Convertible Debt for 1 consecutive years, with $5.0 million as the latest value for Q4 2024.

  • Quarterly Convertible Debt changed N/A to $5.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2024, changed N/A year-over-year, with the annual reading at $5.0 million for FY2024, N/A changed from the prior year.
  • Convertible Debt for Q4 2024 was $5.0 million at NRX Pharmaceuticals, up from $3.0 million in the prior quarter.
  • The five-year high for Convertible Debt was $7.7 million in Q2 2024, with the low at $3.0 million in Q3 2024.